Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
US Stock MarketDetailed Quotes
SRPT Sarepta Therapeutics
- 61.910
- -1.910-2.99%
Close Apr 1 16:00 ET
- 62.320
- +0.410+0.66%
Post 19:11 ET
6.01BMarket Cap26.46P/E (TTM)
65.690High61.525Low3.55MVolume64.370Open63.820Pre Close223.58MTurnover3.84%Turnover Ratio26.46P/E (Static)97.03MShares173.25052wk High3.93P/B5.73BFloat Cap61.52552wk Low--Dividend TTM92.55MShs Float181.830Historical High--Div YieldTTM6.53%Amplitude2.598Historical Low62.990Avg Price1Lot Size
Sarepta Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 52.97%1.9B | 65.94%658.41M | 40.79%467.17M | 38.93%362.93M | 63.10%413.46M | 33.26%1.24B | 53.54%396.78M | 44.10%331.82M | 11.89%261.24M | 20.24%253.5M |
| Operating revenue | 52.97%1.9B | 65.94%658.41M | 40.79%467.17M | 38.93%362.93M | 63.10%413.46M | 33.26%1.24B | 53.54%396.78M | 44.10%331.82M | 11.89%261.24M | 20.24%253.5M |
| Cost of revenue | 112.25%319.1M | 199.49%132.3M | 147.64%91.69M | 30.54%44.55M | 44.38%50.56M | 7.40%150.34M | 43.43%44.18M | -7.32%37.03M | -9.71%34.12M | 11.37%35.02M |
| Gross profit | 44.82%1.58B | 49.21%526.11M | 27.37%375.48M | 40.19%318.39M | 66.10%362.91M | 37.83%1.09B | 54.90%352.61M | 54.89%294.79M | 16.06%227.11M | 21.79%218.48M |
| Operating expense | 0.29%1.36B | 11.11%364.43M | 11.93%353.29M | -11.52%319.09M | -8.01%328M | 2.38%1.36B | -1.94%327.98M | -1.88%315.63M | -11.35%360.63M | 33.91%356.57M |
| Selling and administrative expenses | 15.77%557.87M | 24.43%163.87M | 6.04%128.2M | 17.06%138.8M | 14.71%127M | 6.75%481.87M | 9.31%131.7M | 15.37%120.89M | -23.17%118.56M | 54.11%110.71M |
| -General and administrative expense | 15.77%557.87M | 24.43%163.87M | 6.04%128.2M | 17.06%138.8M | 14.71%127M | --481.87M | --131.7M | 15.37%120.89M | -23.17%118.56M | 54.11%110.71M |
| Research and development costs | -8.30%804.52M | 2.27%199.95M | 15.53%224.48M | -25.71%179.69M | -18.43%200.4M | 0.03%877.39M | -8.55%195.52M | -10.34%194.3M | -4.14%241.89M | 26.48%245.68M |
| Depreciation amortization depletion | 54.27%2.41M | -21.23%601K | 37.13%602K | 235.75%601K | 237.64%601K | 118.35%1.56M | 326.26%763K | 146.63%439K | 0.00%179K | 0.00%178K |
| -Depreciation and amortization | 54.27%2.41M | -21.23%601K | 37.13%602K | 235.75%601K | 237.64%601K | 118.35%1.56M | 326.26%763K | 146.63%439K | 0.00%179K | 0.00%178K |
| Operating profit | 181.43%218.08M | 556.57%161.68M | 206.50%22.2M | 99.47%-701K | 125.28%34.91M | 50.05%-267.82M | 123.05%24.63M | 84.13%-20.84M | 36.76%-133.52M | -58.94%-138.09M |
| Net non-operating interest income expense | -16.55%53.38M | -41.24%10.22M | -23.75%13.42M | -12.33%14.01M | 21.08%15.73M | 350.57%63.96M | 96.21%17.39M | 369.79%17.59M | 217.34%15.98M | 183.38%12.99M |
| Non-operating interest income | -16.52%71.77M | -35.06%14.7M | -19.67%18.33M | -11.14%18.84M | 3.01%19.9M | 210.10%85.97M | 45.49%22.63M | 177.81%22.82M | 780.20%21.2M | 8,883.72%19.32M |
| Non-operating interest expense | -16.44%18.39M | -14.50%4.48M | -5.95%4.92M | -7.50%4.83M | -34.11%4.17M | -58.67%22.01M | -21.74%5.23M | -64.52%5.23M | -67.41%5.22M | -59.97%6.32M |
| Other net income (expense) | 96.62%-10.68M | 90.41%-158K | 94.64%-1.61M | -99.74%268K | 97.63%-9.19M | -146.60%-316.23M | 50.63%-1.65M | 74.76%-29.93M | 3,180.61%102.95M | -22,917.46%-387.61M |
| Special income (charges) | 98.13%-7.84M | 129.08%727K | 105.20%1.54M | --0 | 97.39%-10.1M | -245.26%-418.85M | 2.91%-2.5M | 75.16%-29.5M | --800K | ---387.33M |
| -Less：Restructuring and merger&acquisition | 553.17%7.84M | ---727K | -176.75%-1.54M | --0 | --10.1M | 117.91%1.2M | --0 | 129.85%2M | ---800K | --0 |
| -Less:Other special charges | ---- | ---- | ---- | ---- | ---- | 208.77%387.33M | --0 | ---- | ---- | --387.33M |
| -Write off | --0 | --0 | --0 | ---- | ---- | 1,077.51%30.32M | -2.91%2.5M | --27.5M | ---- | ---- |
| Other non- operating income (expenses) | -102.77%-2.85M | -203.87%-885K | -638.82%-3.14M | -99.74%268K | 420.00%912K | 1,582.69%102.62M | 211.66%852K | -313.57%-425K | 2,286.05%102.15M | 83.08%-285K |
| Income before tax | 150.14%260.77M | 325.41%171.74M | 202.51%34.01M | 193.09%13.58M | 108.08%41.45M | 24.62%-520.1M | 139.85%40.37M | 87.06%-33.17M | 93.61%-14.59M | -392.30%-512.71M |
| Income tax | 60.81%25.54M | 340.23%12.69M | -94.91%395K | -23.92%7.12M | 31.74%5.33M | 17.40%15.88M | -166.57%-5.28M | 488.11%7.76M | 176.12%9.36M | 360.18%4.05M |
| Net income | 143.89%235.24M | 248.37%159.05M | 182.10%33.61M | 126.98%6.46M | 106.99%36.12M | 23.81%-535.98M | 141.79%45.66M | 84.12%-40.94M | 89.66%-23.94M | -392.03%-516.76M |
| Net income continuous Operations | 143.89%235.24M | 248.37%159.05M | 182.10%33.61M | 126.98%6.46M | 106.99%36.12M | 23.81%-535.98M | 141.79%45.66M | 84.12%-40.94M | 89.66%-23.94M | -392.03%-516.76M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 143.89%235.24M | 248.37%159.05M | 182.10%33.61M | 126.98%6.46M | 106.99%36.12M | 23.81%-535.98M | 141.79%45.66M | 84.12%-40.94M | 89.66%-23.94M | -392.03%-516.76M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 143.89%235.24M | 248.37%159.05M | 182.10%33.61M | 126.98%6.46M | 106.99%36.12M | 23.81%-535.98M | 141.79%45.66M | 84.12%-40.94M | 89.66%-23.94M | -392.03%-516.76M |
| Basic earnings per share | 140.34%2.34 | 117.11%1.65 | 176.09%0.35 | 125.93%0.07 | 106.48%0.38 | 27.77%-5.8 | 161.29%0.76 | 84.35%-0.46 | 89.81%-0.27 | -388.33%-5.86 |
| Diluted earnings per share | 140.34%2.34 | 97.37%1.5 | 173.91%0.34 | 125.93%0.07 | 106.31%0.37 | 27.77%-5.8 | 161.29%0.76 | 84.35%-0.46 | 89.81%-0.27 | -388.33%-5.86 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now